An Old but Still Unanswered Question in Recurrent or Metastatic Salivary Duct Carcinoma

Stefano Cavalieri, Laura Deborah Locati, Lisa Licitra
2021 JCO Precision Oncology  
We read with interest the article by Sheth et al recently published in JCO Precision Oncology. The authors reported the case of an androgen receptor-positive (AR+) and human epidermal growth factor receptor 2-positive (HER2+) salivary duct carcinoma (SDC) patient responding to alpelisib and bicalutamide 1 after the progression on first-line paclitaxel, carboplatin, and trastuzumab.
doi:10.1200/po.21.00262 pmid:34994640 fatcat:hy5onykgzjh57njvplq6qmbyzm